[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"aldosterone-disorder\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:aldosterone-disorder":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,47],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100652894","refocus-htn-us-west-a-data-infrastructure-to-characterize-individuals-with-hypertension-100652894",false,"NCT07780500","REFOCUS-HTN US-WEST: A Data Infrastructure to Characterize Individuals With Hypertension","REFOCUS-HTN US-WEST: a Data Infrastructure to Characterize Contemporary Individuals With Hypertension, Their Care, Health Outcomes, and Wellbeing","REFOCUS-HTN","Inclusion Criteria:\n\nThe SCALED Cohort will be identified from the REFOCUS-HTN Cohort which includes men and women ≥ 18 years of age with established hypertension in the KPNC EHR from January 2012 through March 31, 2029. Established hypertension will be defined as one of the following:\n\n* ≥1 outpatient, non-emergency department diagnosis of hypertension;\n* ≥2 consecutive outpatient measures of systolic blood pressure ≥130 mmHg at least 90 days apart;\n* ≥2 consecutive outpatient measures of diastolic blood pressure ≥80 mmHg at least 90 days apart.\n\nAdditional Eligibility Criteria for SCALED:\n\n* Hypertension diagnosis within the past 18 months prior to screening.\n* At least 6 months of continuous health plan coverage prior to initial visit.\n\nExclusion Criteria:\n\n* Diagnosed cause of secondary hypertension from drug or alcohol induced, or renovascular hypertension;\n* Bariatric surgery or GLP1 prescription in the last 12 months;\n* Exposure to an aldosterone synthase inhibitor or a mineralocorticoid receptor antagonist in the last 12 weeks;\n* Last known estimated glomerular filtration rate \\\u003C 45 mL\u002Fmin\u002F1.73m2 (according to the CKD-EPI equation) at the time of screening;\n* Kidney transplant;\n* Currently receiving dialysis;\n* Current enrollment in any cardiovascular or blood pressure interventional trial.","ALL","18 Years",{"count":20,"type":21},500,"ESTIMATED","6 Months","OBSERVATIONAL","The goal of the REFOCUS-HTN US-WEST program is to gain a better understanding of the role of a hormone called aldosterone in the development of hypertension. The SCALED sub-study is an observational cohort study that will enroll from REFOCUS-HTN cohort for prospective data collection.",[26,27,28],"Hypertension","Aldosterone Disorder","Cardiovascular Disease (CVD)",[26,30,31,32,33],"Aldosterone","aldosterone dysregulation","aldosterone disorder","cardiovascular disease (CVD)","RECRUITING","2026-08-14",{"date":37,"type":38},"2026-08-21","ACTUAL",{"date":40,"type":21},"2026-08-20",{"date":42,"type":21},"2029-03",{"name":44,"class":45},"Kaiser Permanente","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":53,"sex":17,"minAge":18,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":46},"100565894","effects-of-sleep-body-temperature-on-body-composition-100565894","NCT06648109","Effects of Sleep Body Temperature on Body Composition","Inclusion Criteria:\n\n\\- Participants aged 18-30 years, inclusive of both male and female genders.\n\nExclusion Criteria:\n\n* Individuals suffering from serious diseases such as heart, liver, kidney, brain, hematopoietic, immune, thyroid, malignant tumors, etc.;\n* Those with familial hereditary hypertension (both parents are hypertensive) or those diagnosed with hypertension;\n* Individuals with cognitive or mental impairments that prevent the completion of the questionnaire;\n* Persons with physical disabilities that hinder normal walking;\n* Persons who have experienced a weight change of \\>3.0 kg within 1 month or \\>10 kg within 6 months prior to screening (as per the study in Nutrients. 2020 Oct 21;12(10):3221);\n* Individuals required to take antibiotics from one week before the trial starts until its conclusion;\n* Those with habitual diarrhea or who have experienced diarrhea from one week before the trial starts until its end;\n* Subjects who have participated in other ambient temperature-related trials within the last 6 months;\n* Individuals with extreme sleep schedules (i.e., not falling asleep between 21:00 and 2:00 a.m. the following morning, or waking up before 5:00 a.m.);\n* Those with sleep latency (the time it takes to fall asleep after going to bed) greater than one hour;\n* Pittsburgh Sleep Quality Index (PSQI) scores greater than 16;\n* Participants who do not sign the informed consent form or are deemed unsuitable by the investigator for any other reason.",true,"30 Years",{"count":56,"type":21},40,"INTERVENTIONAL",[59],"NA","This will be a crossover controlled trial designed to recruit 40 participants, who will be divided into two groups of 20 subjects each. The participants will be randomly assigned to either Group A or Group B. Group A will receive the sleep electric blanket intervention for a period of 7 days, while Group B will serve as the control group without any additional intervention. After the intervention period, there will be a washout period of 7 days to ensure that any effects of the intervention have subsided before the crossover.\n\nFollowing the washout period, the groups will switch roles: Group B will then receive the sleep electric blanket intervention, and Group A will become the control group. This second phase will also last for 7 days, preceded and followed by the same assessment procedures as the initial phase. This design will allow for a comparison of the intervention's effects against a control period within the same group of participants, enhancing the study's internal validity.",[62,63,27],"Blood Pressure Check (Hypertension Screening)","Heart Rate","NOT_YET_RECRUITING","2024-10-17",{"date":67,"type":38},"2024-10-18",{"date":69,"type":21},"2024-10-20",{"date":71,"type":21},"2025-01-30",{"name":73,"class":45},"Jinan University Guangzhou"]